High Tech Medical Kft.

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Familial hypercholesterolaemia2 trials
• Fatty liver disease (MASLD/MASH)2 trials
• Migraine2 trials
• Chronic spontaneous urticaria1 trial
• Liver cirrhosis1 trial
• Stroke1 trial

Phase

• Phase 36 trials
• Phase 21 trial

Status

• Completed4 trials
• Active, not recruiting2 trials
• Recruiting1 trial

Lead sponsor

• Amgen2 trials
• AstraZeneca1 trial
• Astrazeneca AB1 trial
• Curateq Biologics Private Limited1 trial
• Hoffmann-La Roche1 trial
• and 1 more

Running trials

• Active, not recruiting

  A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

  NCT07000136· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

  NCT06419374· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Inventiva Pharma· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)1 recruiting
• Liver cirrhosis1 recruiting

Closed trials

• Completed

  A study to investigate the effect of different doses of AZD0780 on low-density lipoprotein cholesterol (LDL-C) levels compared with placebo and its safety and tolerability in participants 18 to 75 years of age with dyslipidemia

  2023-506197-12-00· Phase 2· Astrazeneca AB· Source

• Completed

  BP11 Versus EU-Approved Xolair® in Patients With Chronic Spontaneous Urticaria

  2024-514764-72-00· Phase 3· Curateq Biologics Private Limited· Source

• Completed

  Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

  NCT03832998· Phase 3· Amgen· Source

• Active, not recruiting

  Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine

  NCT03836040· Phase 3· Amgen· Source